United Therapeutics Cash Flow Statement
NASDAQ: UTHRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
United Therapeutics free cash flow
In fiscal 2025, United Therapeutics generated $1.56 billion of operating cash flow and spent $520.5 million on capital expenditures. That left free cash flow of $1.04 billion, a free-cash-flow margin of 32.7% of revenue. Free cash flow was down 3.7% from the prior year's $1.08 billion.
United Therapeutics returned $1.00 billion to shareholders through share repurchases, equal to 96% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
United Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 1.33B | 1.20B | 984.80M | 727.30M | 475.80M | 514.80M | -104.50M | 589.20M | 417.90M | 713.70M |
| Net Income growth (YoY) | +11.68% | +21.35% | +35.40% | +52.86% | -7.58% | — | -117.74% | +40.99% | -41.45% | +9.53% |
| Depreciation & Amortization | 85.60M | 72.50M | 53.20M | 51.30M | 49.90M | 49.90M | 45.90M | 35.90M | 31.00M | 31.60M |
| Stock-Based Compensation | 147.70M | 144.00M | 39.10M | 106.80M | 138.50M | 163.80M | 45.40M | -26.40M | 73.50M | 12.10M |
| Change in Working Capital | -25.60M | -4.60M | -15.00M | 9.40M | -61.30M | 42.90M | 21.00M | 119.70M | -17.00M | -45.60M |
| Operating Cash Flow | 1.56B | 1.33B | 978.00M | 802.50M | 598.20M | 755.70M | -206.60M | 778.40M | 474.20M | 643.60M |
| Capital Expenditures | -520.50M | -246.50M | -230.40M | -138.80M | -120.80M | -59.30M | -83.70M | -184.40M | -86.30M | -38.00M |
| Investing Cash Flow | -551.30M | 417.20M | -719.60M | -811.50M | -486.90M | -738.50M | -335.40M | -820.60M | -835.60M | 48.30M |
| Share Repurchases | -1.00B | -1.00B | 0 | 0 | — | — | — | — | -250.00M | -500.00M |
| Financing Cash Flow | -1.15B | -1.25B | -11.90M | 75.40M | 44.80M | -16.90M | 611.20M | 6.30M | 43.30M | -497.70M |
| Net Change in Cash | -140.10M | 489.50M | 246.50M | 66.40M | 156.10M | 300.00K | 69.20M | -35.90M | -317.90M | 191.20M |
| Free Cash Flow | 1.04B | 1.08B | 747.60M | 663.70M | 477.40M | 696.40M | -290.30M | 594.00M | 387.90M | 605.60M |
This table shows 10 annual periods of United Therapeutics's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow UTHR's reporting calendar. What is a cash flow statement?